At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IAM Iambic Therapeutics
Trading 11-05 15:35:18 EST
11.18
-2.22
-16.57%
High13.22Low10.55Vol682.51K
Open13.16D1 Closing13.40Amplitude19.93%
Mkt Cap529.94MTradable Cap104.81MTotal Shares47.40M
T/O7.96MT/O Rate7.28%Tradable Shares9.38M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

BIO-key Deploys Identity Security Solution to New Customer Within a Middle East Government’s National Security Ecosystem
GlobeNewswire  ·  10-28
BIO-key Deploys Identity Security Solution to New Customer Within a Middle East Government’s National Security Ecosystem
Iambic Reports Durable Responses to Iam1363 in Phase 1/1b Cancer Trial
Reuters  ·  10-26
Iambic Reports Durable Responses to Iam1363 in Phase 1/1b Cancer Trial
Iambic Presents Updated Iam1363 Clinical Data at Esmo 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with Her2-Driven Cancers
THOMSON REUTERS  ·  10-26
Iambic Presents Updated Iam1363 Clinical Data at Esmo 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with Her2-Driven Cancers
Iambic Therapeutics - More than Half of Participants at 960 Mg Remain on Study Beyond One Year
THOMSON REUTERS  ·  10-26
Iambic Therapeutics - More than Half of Participants at 960 Mg Remain on Study Beyond One Year
Biotech Is Beating AI in the October IPO Market
Bellwether Stocks Movement  ·  10-25
Biotech Is Beating AI in the October IPO Market
Iambic Therapeutics Director Evan Lockwood Rachlin Reports $11.5 Million Common Share Acquisition
Reuters  ·  10-20
Iambic Therapeutics Director Evan Lockwood Rachlin Reports $11.5 Million Common Share Acquisition
Small U.S. Stocks End Mixed as Disc Medicine Leads, Iambic Therapeutics Lags
Dow Jones  ·  10-20
Small U.S. Stocks End Mixed as Disc Medicine Leads, Iambic Therapeutics Lags
Nvidia-Backed Iambic Therapeutics Tumbles Below IPO Price
Reuters  ·  10-19
Nvidia-Backed Iambic Therapeutics Tumbles Below IPO Price
Iambic Therapeutics Completes IPO and Updates Governance
TIPRANKS  ·  10-17
Iambic Therapeutics Completes IPO and Updates Governance
Top Midday Gainers
MT Newswires Live  ·  10-17
Top Midday Gainers
From Algorithms To Oncology: Why IAM Jumped On Day One
Bellwether Stocks Movement  ·  10-16
From Algorithms To Oncology: Why IAM Jumped On Day One
Cathie Wood's ARK Reveals Latest Portfolio Moves: Adds More CoreWeave, Buys Nearly $19 Million in Iambic Shares, Trims Amazon and Palantir
Deep News  ·  10-16
Cathie Wood's ARK Reveals Latest Portfolio Moves: Adds More CoreWeave, Buys Nearly $19 Million in Iambic Shares, Trims Amazon and Palantir
Cathie Wood’s ARK Investment buys 1.18M shares of Iambic Therapeutics today
TIPRANKS  ·  10-16
Cathie Wood’s ARK Investment buys 1.18M shares of Iambic Therapeutics today
Nvidia-Backed Iambic Therapeutics Jumps in Debut After $150 Million IPO
Reuters  ·  10-16
Nvidia-Backed Iambic Therapeutics Jumps in Debut After $150 Million IPO
AI Cancer-Fighting Iambic Therapeutics Stock (IAM) Rockets 13% After $150M IPO
TIPRANKS  ·  10-16
AI Cancer-Fighting Iambic Therapeutics Stock (IAM) Rockets 13% After $150M IPO
Iambic Therapeutics Shares Rise in Nasdaq Debut
MT Newswires Live  ·  10-16
Iambic Therapeutics Shares Rise in Nasdaq Debut
NASDAQ Trade Halt Volatility Trading Pause at 12:12 Pm
Reuters  ·  10-16
NASDAQ Trade Halt Volatility Trading Pause at 12:12 Pm
Iambic Therapeutics Prices $150 Million Initial Public Offering
MT Newswires Live  ·  10-15
Iambic Therapeutics Prices $150 Million Initial Public Offering
NASDAQ Trade Halt Reason not Available at 04:00 Am
Reuters  ·  10-15
NASDAQ Trade Halt Reason not Available at 04:00 Am
Nvidia-backed AI cancer drug developer Iambic (IAM.US) debuts on Nasdaq: priced at midpoint of range, raising $150 million
Stock News  ·  10-15
Nvidia-backed AI cancer drug developer Iambic (IAM.US) debuts on Nasdaq: priced at midpoint of range, raising $150 million

Introduction

Company Name.
Iambic Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Iambic Therapeutics, Inc. is a technology and clinical-stage life sciences company using its Molecular Transformer and proprietary molecular intelligence platform to transform biopharmaceutical discovery. The platform combines large-scale artificial intelligence with automated, scalable chemistry and biology experiments to discover and develop novel medicines.
Issue price:
--